Changes in Beneficial Ownership · 4
Aclarion, Inc.
ACONNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-06-11
- Issuer
- Aclarion, Inc.
- Issuer CIK
- 0001635077
- Trading symbol
- ACON
Reporting owner 1
- Name
- Neal David K
- Reporting owner CIK
- 0001906671
- Relationship
- Director
- Address
- C/O ACLARION, INC., 8181 ARISTA PLACE, SUITE 100, BROOMFIELD, CO, 80021
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-06-11 | A · Form 4 | 20,000[F1][F2] | A | 0.00 | 22,502 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The shares reported are restricted stock units ("RSUs") granted 6/11/2026 under the Company's equity incentive plan. Each RSU represents a contingent right to receive one share of ACON common stock.↩ 1
- F2
- 100% of the RSUs shall vest on 6/1/2027. Any outstanding and unvested RSUs will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).↩ 1
Signature 1
- Signed
- /s/ David K. Neal
- Date
- 2026-06-12
Company context
We are a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), and proprietary biomarkers to optimize clinical treatments. Our technology addresses the $134.5B U.S. low back and neck pain market, which according to a 2020 JAMA (Journal of the American Medical Association) article is now the most costly healthcare condition in the United States. We are currently utilizing Artificial Intelligence (“AI”) to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. The use of AI in this application is early in its development cycle and is expected to evolve with further research and development. We are capturing in databases both the raw spectroscopy data and the post-processed spectral data from every Nociscan completed in order to utilize this data as future training data to teach a machine learning algorithms to associate MRS data with clinical outcomes. The use of AI in this application is aspirational and we intend this type of AI research and development to be an ongoing process applied not only to the various treatment paths associated with back pain, such as conservative therapies, regenerative and cell therapies and surgical intervention, but also to potentially expand into other clinical explorations involving the diagnosis of brain, breast and prostate tumors.